UK markets closed
  • FTSE 100

    7,439.74
    -8.32 (-0.11%)
     
  • FTSE 250

    20,051.48
    -104.32 (-0.52%)
     
  • AIM

    920.38
    -2.34 (-0.25%)
     
  • GBP/EUR

    1.1851
    -0.0010 (-0.09%)
     
  • GBP/USD

    1.2073
    -0.0085 (-0.70%)
     
  • BTC-GBP

    19,226.54
    -71.44 (-0.37%)
     
  • CMC Crypto 200

    533.20
    -2.02 (-0.38%)
     
  • S&P 500

    4,145.19
    -6.75 (-0.16%)
     
  • DOW

    32,803.47
    +76.67 (+0.23%)
     
  • CRUDE OIL

    88.53
    -0.01 (-0.01%)
     
  • GOLD FUTURES

    1,792.40
    -14.50 (-0.80%)
     
  • NIKKEI 225

    28,175.87
    +243.67 (+0.87%)
     
  • HANG SENG

    20,201.94
    +27.94 (+0.14%)
     
  • DAX

    13,573.93
    -88.77 (-0.65%)
     
  • CAC 40

    6,472.35
    -41.04 (-0.63%)
     

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·13-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Lille, France; Cambridge, MA; July 08, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced the half-year report of the liquidity contract with Crédit Industriel et Commercial.

Under the liquidity contract GENFIT has with Crédit Industriel et Commercial, the following resources appeared on the liquidity account as of June 30, 2022:

  • 160,021 shares

  • €449,526.73

During the first half of 2022, total trading was:

  • On the buy side: 584,445 shares for a total amount of €2,076,404.94

  • On the sell side: 561,436 shares for a total amount of €2,013,057.81

During this same period, the number of trades were:

  • On the buy side: 2,452

  • On the sell side: 2,289

As a reminder, upon signing of the contract, the following resources appeared on the liquidity account:

  • 27, 911 shares

  • €769 849,43

ABOUT GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Thanks to its expertise in bringing early-stage assets with high potential to late development and pre-commercialization stages, today GENFIT boasts a growing and diversified pipeline of innovative therapeutic and diagnostic solutions.

Its R&D is focused on three franchises: cholestatic diseases, Acute on Chronic Liver Failure (ACLF) and NASH diagnostics. In its cholestatic diseases franchise, ELATIVE™, a Phase 3 global trial evaluating elafibranor1 in patients with Primary Biliary Cholangitis (PBC) is well underway following a successful Phase 2 clinical trial. Topline data is expected to be announced in the second quarter 2023. In 2021, GENFIT signed an exclusive licensing agreement with IPSEN to develop, manufacture and commercialize elafibranor in PBC and other indications. 2 GENFIT is also developing GNS5611 in cholangiocarcinoma following the acquisition of exclusive rights in this indication from Genoscience Pharma in 20213. In ACLF, a Phase 1 clinical program with nitazoxanide has been initiated with data expected as early as the third quarter 2022. As part of its diagnostic solutions franchise, the Company entered into an agreement with Labcorp in 2021 to commercialize NASHnext®, powered by GENFIT’s proprietary diagnostic technology NIS4® in identifying at-risk NASH.

GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital. www.genfit.com

GENFIT FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s research and development programs. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2021 Universal Registration Document filed with the AMF on 29 April 2022 under n° D.22-0400, which is available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACT

GENFIT | Investors

Tel: +33 3 2016 4000 | investors@genfit.com

PRESS RELATIONS | Media

Stephanie Boyer – Press relations | Tel: +333 2016 4000 | stephanie.boyer@genfit.com

        

APPENDIX
H1 2022

 

Buy side

Sell side

Date

Number of executions

Number of shares

Traded amounts in EUR

Number of executions

Number of shares

Traded amounts in EUR

TOTAL

2 452

584 445

2 076 404,94

2 289

561 436

2 013 057,81

03/01/2022

9

3306

14 178,54

26

24178

105 091,23

04/01/2022

21

11100

47 674,23

17

8231

35 689,53

05/01/2022

24

9200

38 125,31

12

4500

18 636,97

06/01/2022

20

7640

31 321,78

17

9372

38 685,28

07/01/2022

9

2161

9 017,63

10

3908

16 346,58

10/01/2022

18

8431

35 610,37

30

13734

58 414,80

11/01/2022

16

9019

38 753,19

20

7034

30 405,12

12/01/2022

15

5986

25 237,79

13

2572

10 985,69

13/01/2022

14

5861

24 243,44

12

6857

28 540,03

14/01/2022

17

5591

23 246,30

11

4595

19 157,51

17/01/2022

11

6360

26 481,61

9

2578

10 822,64

18/01/2022

3

1784

7 308,34

7

2822

11 698,30

19/01/2022

20

8895

36 196,46

5

1874

7 673,99

20/01/2022

11

3884

15 512,77

5

3810

15 332,51

21/01/2022

40

14639

57 468,09

27

11125

43 793,98

24/01/2022

88

39216

146 897,80

47

20027

74 427,72

25/01/2022

17

8825

32 471,56

19

8323

30 840,72

26/01/2022

23

12601

45 417,18

29

12170

44 129,41

27/01/2022

34

17407

61 300,61

26

11049

38 977,85

28/01/2022

20

4301

14 925,46

12

2995

10 406,68

31/01/2022

19

8384

29 656,82

63

17147

61 141,86

01/02/2022

6

2250

8 134,54

32

6939

25 362,73

02/02/2022

6

2314

8 523,79

9

2365

8 807,67

03/02/2022

22

9179

32 912,54

3

745

2 696,94

04/02/2022

33

7261

25 277,27

15

2765

9 643,47

07/02/2022

31

4599

15 560,50

43

4353

14 807,18

08/02/2022

56

15323

53 900,34

58

18486

65 196,58

09/02/2022

21

2936

10 220,05

16

2957

10 343,96

10/02/2022

12

2536

8 810,88

17

3275

11 468,12

11/02/2022

12

4798

17 057,75

25

8850

31 577,34

14/02/2022

47

11538

40 461,00

26

6938

24 416,43

15/02/2022

13

3941

13 926,14

25

9039

32 067,63

16/02/2022

11

5139

18 692,17

35

12386

45 099,35

17/02/2022

25

8790

31 775,33

11

3448

12 496,47

18/02/2022

19

5047

18 016,43

12

3825

13 758,18

21/02/2022

10

2137

7 551,87

13

2757

9 800,67

22/02/2022

34

5882

20 392,99

22

4832

16 864,54

23/02/2022

6

2737

9 832,38

13

4407

15 876,33

24/02/2022

54

10901

36 390,62

40

7272

24 232,79

25/02/2022

16

1914

6 485,05

26

4630

15 753,43

28/02/2022

23

3901

13 092,34

14

2667

9 024,14

01/03/2022

15

4225

14 842,10

25

6491

23 195,92

02/03/2022

12

2448

8 300,92

17

3816

13 043,23

03/03/2022

38

7726

26 714,14

14

2700

9 447,03

04/03/2022

32

6841

22 201,05

16

2953

9 635,71

07/03/2022

38

9360

27 925,73

28

7512

22 623,99

08/03/2022

18

3638

11 283,89

40

8864

27 868,82

09/03/2022

55

11116

37 925,96

92

16899

57 662,35

10/03/2022

29

5792

19 587,31

34

6866

23 585,66

11/03/2022

26

3881

13 017,65

22

4030

13 676,39

14/03/2022

10

805

2 775,16

19

4377

15 116,94

15/03/2022

21

2024

7 009,31

8

1386

4 816,80

16/03/2022

10

1974

6 914,34

12

2619

9 218,92

17/03/2022

19

3686

13 004,69

20

4153

14 709,41

18/03/2022

7

1497

5 275,46

13

2216

7 882,91

21/03/2022

4

625

2 212,50

3

615

2 189,38

22/03/2022

9

1341

4 763,55

7

1653

5 903,35

23/03/2022

13

2079

7 470,76

13

2079

7 512,32

24/03/2022

8

884

3 141,53

3

198

704,90

25/03/2022

6

992

3 497,26

5

798

2 841,80

28/03/2022

9

1729

6 201,75

19

2095

7 545,75

29/03/2022

12

1652

5 923,35

22

1718

6 196,29

30/03/2022

7

1084

3 907,01

7

1650

5 982,61

31/03/2022

11

1751

6 349,88

4

1070

3 913,64

01/04/2022

5

483

1 733,32

5

195

703,57

04/04/2022

5

757

2 741,29

6

1129

4 114,21

05/04/2022

4

561

2 019,42

1

200

726,00

06/04/2022

14

1618

5 709,07

12

1266

4 485,94

07/04/2022

12

1397

4 982,18

15

2225

7 993,03

08/04/2022

25

4871

17 985,86

21

4432

16 502,16

11/04/2022

16

2989

11 158,93

31

5656

21 163,50

12/04/2022

35

4412

16 375,52

16

3518

13 117,43

13/04/2022

14

2406

9 184,39

24

5389

20 716,48

14/04/2022

20

3785

14 691,40

9

2054

8 026,12

19/04/2022

13

2110

7 827,16

11

1277

4 725,65

20/04/2022

21

2267

8 300,35

6

858

3 151,42

21/04/2022

9

1559

5 683,40

10

1789

6 556,05

22/04/2022

20

3423

12 168,89

 

 

 

25/04/2022

15

2913

9 990,13

16

3169

10 936,69

26/04/2022

12

1312

4 493,46

3

441

1 526,59

27/04/2022

20

3212

10 703,78

12

2388

8 004,66

28/04/2022

23

3943

13 121,21

21

2820

9 638,93

29/04/2022

12

3375

11 225,24

15

4763

15 928,73

02/05/2022

11

1642

5 457,63

15

1325

4 437,78

03/05/2022

7

1107

3 725,96

10

1358

4 619,35

04/05/2022

13

1517

5 033,26

4

381

1 273,35

05/05/2022

23

3801

12 440,26

33

3414

11 290,28

06/05/2022

16

2489

7 968,97

8

1040

3 349,30

09/05/2022

13

1149

3 602,71

3

267

843,15

10/05/2022

13

1169

3 617,64

4

473

1 468,75

11/05/2022

8

1121

3 524,69

15

2025

6 388,48

12/05/2022

22

3850

11 856,64

18

2624

8 106,02

13/05/2022

16

2627

8 208,74

23

3716

11 683,77

16/05/2022

22

3271

10 357,48

17

2967

9 495,71

17/05/2022

18

1624

5 190,33

26

3533

11 303,12

18/05/2022

16

1657

5 436,67

20

3246

10 687,19

19/05/2022

10

1151

3 823,03

19

2512

8 442,74

20/05/2022

13

1529

5 214,85

3

637

2 204,02

23/05/2022

15

2201

7 475,95

25

2764

9 449,63

24/05/2022

39

5916

19 773,02

11

1425

4 781,07

25/05/2022

27

8554

27 116,26

17

8426

26 938,92

26/05/2022

11

1944

6 300,93

5

1944

6 339,79

27/05/2022

4

2264

7 365,92

11

2173

7 146,57

30/05/2022

3

472

1 598,13

44

4998

16 868,54

31/05/2022

32

5457

18 396,97

11

1234

4 199,76

01/06/2022

24

3915

12 866,86

3

361

1 194,60

02/06/2022

21

2731

8 836,98

13

1876

6 130,70

03/06/2022

3

193

621,46

27

4764

15 684,31

06/06/2022

23

3562

11 975,98

35

6102

20 725,91

07/06/2022

45

5299

17 431,01

20

2888

9 510,53

08/06/2022

15

1901

6 378,51

35

5146

17 262,43

09/06/2022

36

6950

23 089,95

12

3887

12 942,17

10/06/2022

25

5298

17 382,89

7

1764

5 832,74

13/06/2022

54

10474

33 129,11

15

2153

6 742,24

14/06/2022

36

8856

27 230,31

71

16983

53 354,95

15/06/2022

44

9875

31 189,84

21

2418

7 640,52

16/06/2022

42

8513

26 333,43

64

9792

30 510,51

17/06/2022

26

6439

20 181,95

17

4092

13 050,04

20/06/2022

4

771

2 401,10

4

524

1 643,39

21/06/2022

2

254

792,49

2

254

801,60

22/06/2022

16

1054

3 302,48

4

417

1 315,79

23/06/2022

16

3511

10 970,78

3

160

504,63

24/06/2022

7

2375

7 460,52

13

4940

15 641,60

27/06/2022

27

9199

29 058,16

9

7718

24 595,00

28/06/2022

1

1

3,10

10

8153

25 469,48

29/06/2022

5

727

2 253,70

4

727

2 268,22

30/06/2022

18

3778

11 628,76

9

1671

5 135,52


1 Elafibranor and GNS561 are investigational compounds that have not been reviewed nor been approved by a regulatory authority
2 With the exception of China, Hong Kong, Taiwan, and Macau where Terns Pharmaceuticals holds the exclusive license to develop and commercialize elafibranor
3 Agreement includes commercialization and development in the United States, Canada and Europe, including the United Kingdom and Switzerland

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting